You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

Steven Leonard Chapman net worth and biography

Steven Chapman Biography and Net Worth

CEO of Natera

Steven “Steve” Chapman is the CEO of Natera, a global leader in cell-free DNA testing with a focus on women's health, oncology, and organ health. Chapman has been in the role of CEO since 2019, and he also sits on the board of directors.

Chapman has been with Natera since 2010, previously serving as chief operating officer, chief commercial officer, senior vice president for commercial operations and vice president of sales. As COO, he led Natera’s commercial entry to the competitive non-invasive prenatal testing market, in which itsPanorama® test reached market leader-status despite being fourth to market.

In his role as CEO, Chapman has played an instrumental role in expanding Natera’s core technology to address new oncology and organ health markets, securing swift commercial growth for the Prospera™ transplant assessment test and establishing the company’s leadership in molecular residual disease testing via Signatera.™ During his tenure, the company has seen year-over-year growth in revenue of more than 40 percent, consistently outperforming earnings expectations.

Before joining Natera, he worked with Genzyme Genetics, a biotechnology company. While there, Chapman delivered record-breaking commercial growth and led strategies that altered pregnancy genetic testing. He started his career as a researcher in the human genetics department at the University of California, Los Angeles, where he earned his B.S. in microbiology, immunology and molecular genetics.

What is Steven Leonard Chapman's net worth?: The estimated net worth of Steven Leonard Chapman is at least $4.54 million as of January 23rd, 2023. Mr. Chapman owns 103,779 shares of Natera stock worth more than $4,539,293 as of January 28th. This net worth estimate does not reflect any other investments that Mr. Chapman may own. Additionally, Mr. Chapman receives a salary of $925,590.00 as CEO at Natera. Learn More about Steven Leonard Chapman's net worth.
How old is Steven Leonard Chapman?: Mr. Chapman is currently 44 years old. There are 5 older executives and no younger executives at Natera. Learn More on Steven Leonard Chapman's age.
What is Steven Leonard Chapman's salary?: As the CEO of Natera, Inc., Mr. Chapman earned a total compensation package of $23,304,147.00 in 2021. Mr. Chapman earned a salary of $525,732.00, stock awards of $14,031,437.00, options awards of $8,386,125.00, non-equity compensation of $391,153.00, and other compensation of $8,700.00. Learn More on Steven Leonard Chapman's salary.
How do I contact Steven Leonard Chapman?: The corporate mailing address for Mr. Chapman and other Natera executives is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. Natera can also be reached via phone at (650) 249-9090 and via email at [email protected] Learn More on Steven Leonard Chapman's contact information.
Has Steven Leonard Chapman been buying or selling shares of Natera?: During the past quarter, Steven Leonard Chapman has sold $547,961.80 of Natera stock. Most recently, Steven Leonard Chapman sold 5,370 shares of the business's stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $41.56, for a transaction totalling $223,177.20. Following the completion of the sale, the chief executive officer now directly owns 103,779 shares of the company's stock, valued at $4,313,055.24. Learn More on Steven Leonard Chapman's trading history.
Who are Natera's active insiders?: Natera's insider roster includes Roy Baynes (Director), Roelof Botha (Director), Michael Brophy (CFO), Rowan Chapman (Director), Steven Chapman (CEO), Todd Cozzens (Director), James Healy (Director), Gail Marcus (Director), Daniel Rabinowitz (Insider), Matthew Rabinowitz (Chairman), Herm Rosenman (Director), Robert Schueren (COO), and Jonathan Sheena (Insider). Learn More on Natera's active insiders.
Are insiders buying or selling shares of Natera?: During the last twelve months, Natera insiders bought shares 2 times. They purchased a total of 372,820 shares worth more than $11,323,786.80. During the last twelve months, insiders at the medical research company sold shares 60 times. They sold a total of 96,087 shares worth more than $3,913,739.28. The most recent insider tranaction occured on January, 23rd when insider Daniel Rabinowitz sold 2,387 shares worth more than $99,203.72. Insiders at Natera own 10.3% of the company. Learn More about insider trades at Natera.
Information on this page was last updated on 1/23/2023.

Steven Leonard Chapman Insider Trading History at Natera

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/23/2023	Sell	5,370	$41.56	$223,177.20	103,779
1/3/2023	Sell	8,212	$39.55	$324,784.60	93,831
12/28/2022	Sell	2,605	$39.84	$103,783.20	85,210
12/23/2022	Sell	1,660	$42.30	$70,218.00	82,632
12/7/2022	Sell	2,645	$38.31	$101,329.95	80,985
10/24/2022	Sell	905	$42.41	$38,381.05	73,326
10/3/2022	Sell	1,559	$44.43	$69,266.37	72,457
9/28/2022	Sell	2,606	$44.04	$114,768.24	70,891
9/23/2022	Sell	1,674	$45.30	$75,832.20	68,313
7/22/2022	Sell	886	$46.26	$40,986.36	69,805
7/5/2022	Sell	1,550	$36.93	$57,241.50	68,916
6/28/2022	Sell	2,619	$39.01	$102,167.19	67,341
6/23/2022	Sell	1,652	$35.76	$59,075.52	64,777
4/22/2022	Sell	894	$36.14	$32,309.16	63,122
4/4/2022	Sell	1,559	$43.09	$67,177.31	62,242
3/28/2022	Sell	2,605	$39.63	$103,236.15
3/23/2022	Sell	1,682	$40.60	$68,289.20
3/10/2022	Sell	1,147	$42.16	$48,357.52
1/24/2022	Sell	3,686	$59.95	$220,975.70
1/5/2022	Sell	4,995	$82.61	$412,636.95
1/3/2022	Sell	29,167	$88.27	$2,574,571.09
12/28/2021	Sell	2,604	$91.34	$237,849.36
12/23/2021	Sell	1,657	$93.00	$154,101.00
12/10/2021	Sell	1,145	$91.33	$104,572.85
12/7/2021	Sell	4,726	$91.99	$434,744.74
12/1/2021	Sell	7,219	$90.80	$655,485.20
11/1/2021	Sell	6,652	$115.64	$769,237.28
10/4/2021	Sell	6,653	$108.65	$722,848.45
9/28/2021	Sell	2,698	$109.72	$296,024.56
9/23/2021	Sell	1,649	$125.67	$207,229.83
9/10/2021	Sell	80,826	$119.72	$9,676,488.72
8/12/2021	Sell	33,356	$101.66	$3,390,970.96	74,986
7/6/2021	Sell	27,832	$117.05	$3,257,735.60	77,755
6/28/2021	Sell	2,604	$117.57	$306,152.28	77,234
6/23/2021	Sell	1,662	$115.18	$191,429.16	70,588
6/14/2021	Sell	26,092	$103.61	$2,703,392.12	78,582
6/10/2021	Sell	1,158	$102.61	$118,822.38	79,714
6/4/2021	Sell	4,709	$97.51	$459,174.59	82,127
5/14/2021	Sell	13,007	$93.05	$1,210,301.35	72,752
4/13/2021	Sell	41,650	$104.21	$4,340,346.50	127,409
4/5/2021	Sell	1,558	$104.09	$162,172.22	46,037
3/29/2021	Sell	11,476	$83.95	$963,410.20	37,185
3/23/2021	Sell	2,241	$102.55	$229,814.55	29,210
3/11/2021	Sell	17,922	$99.63	$1,785,568.86	36,942
3/9/2021	Sell	22,327	$99.30	$2,217,071.10	38,059
3/3/2021	Sell	1,390	$115.00	$159,850.00	38,554
2/1/2021	Sell	3,840	$108.12	$415,180.80	37,689
1/13/2021	Sell	8,155	$115.00	$937,825.00	38,282
1/4/2021	Sell	4,890	$99.49	$486,506.10	38,722
12/22/2020	Sell	5,056	$105.48	$533,306.88	37,879
12/10/2020	Sell	1,163	$92.60	$107,693.80	29,667
11/11/2020	Sell	94,379	$77.98	$7,359,674.42	39,660
11/4/2020	Sell	61,351	$75.00	$4,601,325.00	39,088
10/12/2020	Sell	210	$75.00	$15,750.00
10/5/2020	Sell	11,185	$71.24	$796,819.40	45,170
9/22/2020	Sell	558	$62.69	$34,981.02	25,332
9/10/2020	Sell	1,184	$60.77	$71,951.68	25,399
9/4/2020	Sell	9,720	$61.56	$598,363.20	32,823
8/6/2020	Sell	61,565	$55.00	$3,386,075.00	26,002
7/6/2020	Sell	13,237	$48.97	$648,215.89	27,675
7/2/2020	Sell	11,678	$49.06	$572,922.68	27,675
6/24/2020	Sell	4,771	$45.47	$216,937.37	29,321
6/22/2020	Sell	39,354	$45.09	$1,774,471.86	26,415
6/16/2020	Sell	4,457	$45.00	$200,565.00	26,433
6/10/2020	Sell	17,304	$42.38	$733,343.52	40,882
4/3/2020	Sell	1,564	$27.50	$43,010.00	11,196
3/23/2020	Sell	7,424	$24.10	$178,918.40	2,268
3/10/2020	Sell	1,147	$33.36	$38,263.92	2,297
1/16/2020	Sell	139,340	$35.00	$4,876,900.00	32,540
1/7/2020	Sell	1,849	$35.00	$64,715.00	24,571
1/3/2020	Sell	4,739	$32.01	$151,695.39	27,461
12/23/2019	Sell	558	$36.93	$20,606.94	15,519
9/23/2019	Sell	559	$33.53	$18,743.27	13,813
9/20/2019	Sell	9,424	$33.19	$312,782.56	22,120
9/10/2019	Sell	1,155	$29.50	$34,072.50	4,525
8/9/2019	Sell	98,996	$33.00	$3,266,868.00	20,061
6/24/2019	Sell	390	$25.19	$9,824.10	10,242
6/10/2019	Sell	794	$24.79	$19,683.26	9,919
3/22/2019	Sell	384	$20.20	$7,756.80	8,007
3/11/2019	Sell	3,410	$16.00	$54,560.00	10,299
12/24/2018	Sell	565	$12.39	$7,000.35	1,679
10/12/2018	Sell	35,000	$20.66	$723,100.00	24,240
10/2/2018	Sell	35,000	$23.76	$831,600.00	19,022
9/26/2018	Sell	9,200	$24.88	$228,896.00	9,762
9/24/2018	Sell	562	$23.78	$13,364.36	4,324
9/19/2018	Sell	35,000	$23.81	$833,350.00	18,919
9/11/2018	Sell	45,000	$25.16	$1,132,200.00	16,628
6/25/2018	Sell	86,919	$18.00	$1,564,542.00	3,588
3/26/2018	Sell	1,997	$9.74	$19,450.78	4,468

Steven Leonard Chapman Buying and Selling Activity at Natera

Natera Company Overview

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Today's Range

Now: $43.74

$41.89

$44.21

50 Day Range

MA: $39.96

$35.29

$43.74

2 Week Range

Now: $43.74

$26.10

$74.82

Volume

659,164 shs

Average Volume

1,300,920 shs

Market Capitalization

$4.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.28

The Next Big Crisis Is Here

From Porter & Company | Ad

You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.

Click here to watch it, free.

Steven Chapman Biography and Net Worth

What is Steven Leonard Chapman's net worth?

How old is Steven Leonard Chapman?

What is Steven Leonard Chapman's salary?

How do I contact Steven Leonard Chapman?

Has Steven Leonard Chapman been buying or selling shares of Natera?

Who are Natera's active insiders?

Are insiders buying or selling shares of Natera?